The NO → sGC → cGMP cascade is a pharmacodynamic pathway describing how nitric oxide activates soluble guanylate cyclase, increasing conversion of GTP to cyclic GMP, followed by regulation of cGMP through phosphodiesterase activity. NO generation is upstream of PDE5 inhibition and provides the signaling input that activates sGC. sGC activation therefore represents the endogenous pathway step that establishes cGMP formation, while PDE5 controls cGMP degradation and turnover. Sildenafil and avanafil act at the PDE5 portion of this system rather than directly generating NO or directly activating sGC. Their PD differences can therefore be represented through PDE5 interaction parameters such as potency, concentration–effect slope, and maximal modeled effect, together with the sensitivity of the downstream cGMP system to altered PDE5 activity. A higher modeled PDE5 inhibitory sensitivity shifts the concentration scale required to alter cGMP turnover, while slope describes how rapidly the modeled response changes across that concentration range. Maximal modeled effect represents the upper asymptotic response of the specified model rather than an independent measure of NO production or sGC capacity. The complete pathway framework is introduced in the overview.
Sildenafil and avanafil can be compared mechanistically by separating their PDE5 interaction properties from the upstream NO–sGC signaling machinery. Differences in modeled potency determine the concentration scale at which PDE5 inhibition changes cGMP degradation, while differences in concentration–effect slope determine the steepness of the modeled transition between lower and higher levels of PDE5 inhibition. A maximal modeled effect parameter determines the upper asymptotic response represented by the PD model. These parameters can generate different modeled response geometries even when the upstream NO generation and sGC activation steps are held constant. PK processes provide the concentration input to this PD system: absorption determines systemic input timing, distribution shapes concentration movement, and metabolism and clearance shape subsequent concentration decline. Consequently, the temporal concentration supplied to the PDE5 interaction model can vary independently of the intrinsic PD relationship. This separation can be examined through onset comparison, peak effect comparison, and duration comparison. The relevant PK determinants are further described through absorption differences, distribution differences, and metabolism differences.
PK and PD variability represent separate sources of variation within the NO/cGMP exposure–effect system. PK variability changes the concentration-time profile delivered to the PDE5 interaction site through differences in absorption, distribution, metabolism, and clearance. Such variation can change when concentrations rise, how the concentration peak forms, and how rapidly concentrations decline. PD variability instead changes the concentration–effect relationship itself, including parameters such as potency, slope, maximal modeled effect, or pathway sensitivity. Within the NO/cGMP cascade, this means that the same concentration-time input can produce different modeled response curves when PD parameters differ, while identical PD parameters can produce different response trajectories when PK exposure differs. The upstream NO generation and sGC activation processes should likewise be distinguished from PDE5 inhibition: sildenafil and avanafil modulate PDE5 activity and thereby alter cGMP turnover rather than serving as direct sources of NO or direct activators of sGC. Separating these layers prevents concentration-time differences from being treated as intrinsic PD differences. The distinction between exposure variability and concentration–effect variability is developed in pk variability and pd variability.
Potency in the NO/cGMP cascade describes the concentration scale at which PDE5 inhibition produces a defined change in cGMP turnover within a specified PD model. NO generation and sGC activation are upstream processes: NO binds to soluble guanylate cyclase, increasing its catalytic activity and promoting cGMP formation from GTP. PDE5 then regulates cGMP degradation. Sildenafil and avanafil do not directly generate NO or activate sGC; their modeled pharmacodynamic action occurs through inhibition of PDE5. Consequently, potency is most directly interpreted as the sensitivity of the PDE5 interaction to drug concentration and the resulting influence on cGMP turnover. A potency parameter can shift the concentration range over which the modeled response moves from lower to higher levels. The resulting response depends on the baseline NO–sGC–cGMP signaling state, PDE5 activity, and the mathematical concentration–effect relationship. A cGMP formation threshold, when included in a model, represents a defined concentration or signaling boundary rather than a universal biological threshold. These pathway relationships provide the PD foundation described in the overview.
Sildenafil and avanafil can exhibit distinct modeled response geometry when their PDE5 potency parameters differ. A shift in potency changes the concentration scale at which inhibition becomes appreciable within the model, while the upstream NO generation and sGC activation steps remain conceptually separate. Because cGMP formation is produced upstream through sGC and cGMP degradation is regulated downstream by PDE5, altering PDE5 inhibition changes the balance between formation and degradation rather than creating a new source of cGMP. The resulting difference can appear in the early concentration–effect region and around the modeled peak response when the PK concentration trajectory crosses different portions of the PD curve. Potency therefore influences response sensitivity without being equivalent to the magnitude of systemic exposure. A PK difference can move the concentration trajectory along an unchanged PD curve, whereas a potency difference changes the PD curve itself. The relationship between concentration and peak response is further considered through peak effect comparison.
| PD Domain | NO/cGMP Determinant | Link |
|---|---|---|
| Potency | Determines the concentration scale for PDE5 interaction. | overview |
| sGC Sensitivity | Determines the modeled sensitivity of NO-driven cGMP formation; not a direct target of sildenafil or avanafil. | peak effect comparison |
| cGMP Formation Threshold | Defines a modeled activation range within the NO–sGC signaling system. | duration comparison |
Slope describes the steepness of the modeled concentration–effect relationship. Within an NO/cGMP framework, it determines how strongly a change in drug concentration alters the modeled degree of PDE5 inhibition across a specified concentration range. Because PDE5 regulates cGMP degradation, changes in PDE5 inhibition can shift the balance between ongoing sGC-mediated cGMP formation and cGMP breakdown. A steeper concentration–effect slope produces a more abrupt modeled transition across the relevant concentration range, whereas a shallower slope distributes the transition more gradually. This parameter should not be interpreted as a change in the intrinsic rate of NO generation or sGC catalytic activity. Instead, it describes the shape of the drug–PDE5 interaction or downstream concentration–effect mapping used in the model. The slope can therefore alter response acceleration as concentration rises or falls without necessarily changing the underlying PK concentration trajectory. The same concentration-time profile can generate different response geometry if slope parameters differ. Conversely, the same slope can produce different temporal responses when PK exposure differs. The pathway framework is anchored by the overview.
For sildenafil and avanafil, differences in modeled slope can produce distinct response geometry around the ascending and descending portions of the concentration trajectory. When concentration rises, a steeper PD relationship produces a more concentrated transition in modeled PDE5 inhibition and downstream cGMP response. When concentration falls, the same slope determines how rapidly the modeled response moves back through the concentration–effect curve. Thus, slope can influence the apparent sharpness of peak and decline geometry without changing the underlying absorption, distribution, metabolism, or clearance processes. The observed temporal response remains the combination of the PK concentration trajectory and the PD concentration–effect function. A change in clearance can alter how long concentration remains within a particular response range, whereas a change in slope alters the response generated within that range. These mechanisms should therefore be separated when interpreting modeled persistence and decline. The resulting relationship to exposure duration is described through duration comparison.
| PD Domain | NO/cGMP Determinant | Link |
|---|---|---|
| Slope | Determines concentration–effect steepness for the modeled PDE5 response. | overview |
| Effect Acceleration | Changes modeled responsiveness to concentration changes. | peak effect comparison |
| Decline Sensitivity | Changes modeled response movement as concentration decreases. | duration comparison |
Maximal modeled effect represents the upper asymptote of the specified concentration–effect model. In an NO/cGMP framework, this parameter describes the highest modeled response attainable as PDE5 inhibition approaches the upper region of its modeled concentration–effect relationship. It should not be equated with unlimited cGMP formation, because cGMP production remains dependent on upstream NO–sGC signaling, substrate availability, guanylate cyclase activity, and the balance between synthesis and degradation. Likewise, the maximal modeled effect is not a direct measure of NO generation or sGC activation. It is a property of the defined PD relationship between drug concentration, PDE5 inhibition, and the downstream response variable. Saturation behavior occurs when increasing concentration produces progressively smaller modeled changes as the response approaches the specified upper asymptote. This separates maximal effect from potency: potency determines where the response curve is positioned along the concentration axis, while maximal modeled effect determines its upper response limit. The conceptual distinction between exposure and modeled effect is established in the overview.
Sildenafil and avanafil can be represented by different maximal modeled-effect parameters if the underlying PD model assigns different upper response limits. Such a difference becomes most apparent in the high-concentration region, where additional concentration produces progressively smaller changes as the response approaches saturation. The resulting plateau geometry is distinct from potency and slope: a potency shift changes the concentration scale, a slope change modifies the steepness of transition, and a maximal-effect change modifies the upper asymptotic boundary. Within the NO/cGMP cascade, the plateau remains downstream of NO generation and sGC-mediated cGMP formation. PDE5 inhibition changes cGMP degradation, so the modeled response reflects the balance between synthesis and degradation rather than direct stimulation of NO production. PK exposure determines which portion of the PD curve is traversed over time, while the maximal-effect parameter determines the upper boundary of that curve. The high-concentration relationship is examined through peak effect comparison.
| PD Domain | NO/cGMP Determinant | Link |
|---|---|---|
| Maximal Modeled Effect | Upper limit of the modeled cGMP-related response. | overview |
| Saturation Sensitivity | Changes modeled plateau behavior as PDE5 inhibition approaches its upper range. | peak effect comparison |
| High-Concentration Response | Changes upper-region concentration–effect geometry. | duration comparison |
The main mechanistic differences arise from the compounds' interaction with PDE5 and the concentration–effect parameters used to represent that interaction. NO generation occurs upstream and activates soluble guanylate cyclase, which increases cGMP formation. PDE5 subsequently regulates cGMP degradation. Sildenafil and avanafil act at PDE5 rather than directly generating NO or activating sGC. Differences in modeled PDE5 potency can shift the concentration scale at which inhibition occurs, while slope determines how sharply the response changes across that concentration range. A maximal modeled effect parameter establishes the upper asymptotic response of the PD model. Pathway sensitivity can additionally describe how changes in PDE5 activity propagate through cGMP turnover under a specified NO–sGC signaling state. These PD parameters should be distinguished from PK parameters, which determine the concentration-time input presented to the PDE5 system. The complete modeled response therefore reflects both the concentration trajectory and the separate concentration–effect relationship.
Potency, slope, and maximal modeled effect describe different properties of a concentration–effect relationship. Potency determines the concentration scale at which a defined degree of PDE5 inhibition or downstream response is produced. Slope determines how rapidly the modeled response changes as concentration moves through that range. Maximal modeled effect establishes the upper asymptotic response reached as the concentration–effect relationship approaches saturation. Within the NO/cGMP cascade, these parameters operate downstream of NO generation and sGC activation. NO activates sGC and promotes cGMP formation, while PDE5 regulates cGMP degradation. Inhibiting PDE5 therefore changes cGMP turnover without directly generating NO or activating sGC. A potency change shifts the curve along the concentration axis, a slope change alters its steepness, and a maximal-effect change alters its upper boundary. These distinctions allow the modeled response geometry of sildenafil and avanafil to be separated into specific PD determinants rather than treating the entire cascade as a single parameter.
PK variability changes the concentration-time trajectory delivered to the PD system. Differences in absorption can alter the timing and magnitude of systemic input, distribution can alter concentration movement between compartments, and metabolism or clearance can alter concentration decline. PD variability instead changes the relationship between concentration and the modeled response. Within the NO/cGMP system, this can involve differences in PDE5 potency, concentration–effect slope, maximal modeled effect, or downstream pathway sensitivity. Therefore, two profiles can have different responses because their concentrations differ while their PD parameters remain identical. Alternatively, the same concentration-time profile can produce different modeled responses when PD parameters differ. The upstream NO–sGC signaling state also remains conceptually separate from the PDE5 interaction. Sildenafil and avanafil inhibit PDE5; they do not serve as direct sources of NO or direct activators of sGC. Separating PK and PD variability therefore identifies whether a modeled difference originates from exposure geometry or from concentration–effect coupling.
NO/cGMP pathway analysis and PK exposure geometry describe different layers of the modeled system. PK determines how concentration changes over time through absorption, distribution, metabolism, and clearance. The NO/cGMP pathway describes how endogenous NO activates sGC, how cGMP is formed, and how PDE5 regulates cGMP degradation. Sildenafil and avanafil interact with PDE5, so their pharmacodynamic parameters describe the concentration-dependent modification of cGMP turnover rather than the processes that determine systemic concentration. A PK change can move the concentration trajectory across an unchanged PDE5 concentration–effect curve. A PD change can alter that curve while leaving the concentration-time trajectory unchanged. This distinction is also important for interpreting peak and duration geometry: a concentration peak is generated by PK processes, whereas the magnitude and shape of the corresponding modeled response depend on PD parameters. Separating these layers prevents absorption, distribution, metabolism, or clearance effects from being incorrectly assigned to NO generation, sGC activation, potency, slope, or maximal modeled effect.